BioSpace News Archive

The cardiac screen is a gadget that shows the electrical and pressing factor waveforms of the cardiovascular framework for estimation and treatment.

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported that its recently acquired German subsidiary, AdVita Lifescience GmbH, has received regulatory clearance to commence a phase 2 clinical trial in Germany to evaluate inhaled aviptadil for the treatment of sarcoidosis.

Fact.MR – A Market Research and Competitive Intelligence Provider: According to the recent study by Fact.MR, the global byler disease market is estimated to exhibit positive growth in the forecast period 2021 to 2031.

Precision BioSciences, Inc. and Tiziana Life Sciences plc announced an exclusive license agreement to explore Tiziana’s foralumab, a fully human anti-CD3 monoclonal antibody, as an agent to induce tolerance of allogeneic CAR T cells to potentially improve the clinical outcome of CAR T cell therapy.

The COVID-19 Immunity Task Force and the Vaccine Surveillance Reference Group are announcing a new study led by Sunnybrook researchers, which seeks to better understand the effectiveness of COVID-19 vaccination in patients with chronic kidney disease.

Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for the treatment of serious and debilitating hematologic diseases, announced a $90 million Series B financing from a leading syndicate of investors.

Novocure announced that Ashley Cordova, Chief Financial Officer, and Pritesh Shah, Chief Commercial Officer, will participate in the 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021.

ICON plc, a world-leading healthcare intelligence and clinical research organisation, announced that Mr. Brendan Brennan, CFO of ICON plc, will present at:.

Alligator Bioscience AB announces that the Company, in order to enable further progress, will begin evaluating potential financing alternatives, which may include issuance of equity.

Gamida Cell Ltd., an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced that company management will present its corporate highlights at the following virtual investor conferences in September.